Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
A Randomized, Placebo-control, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients With MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positive Myasthenia Gravis Patients
Sponsor: Catalyst Pharmaceuticals, Inc.
A PHASE3 clinical study on Myasthenia Gravis, Generalized, this trial is completed. The trial is conducted by Catalyst Pharmaceuticals, Inc. and has accumulated 18 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
18 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Apr 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
▶ Show 13 earlier versions
-
Sep 2021 — Dec 2022 [monthly]
Completed PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE3
-
May 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Mar 2020 — May 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2019 — Mar 2020 [monthly]
Recruiting PHASE3
-
Apr 2019 — Sep 2019 [monthly]
Recruiting PHASE3
-
Mar 2019 — Apr 2019 [monthly]
Recruiting PHASE3
-
Oct 2018 — Mar 2019 [monthly]
Recruiting PHASE3
-
Jul 2018 — Oct 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jan 2018 — Mar 2018 [monthly]
Not Yet Recruiting PHASE3
-
Oct 2017 — Jan 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Catalyst Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .